AstraZeneca PLC (AZN)

AstraZeneca Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	12,914	12,402	8,691	6,899	2,501	-265
Depreciation & Amortization	5,815	5,733	6,688	5,387	5,480	6,530
Other Adjustments	211	422	125	125	-307	-580
Change in Receivables	-	-1,728	-1,624	-1,425	-1,349	-961
Changes in Inventories	-	-755	-131	-669	3,941	1,577
Changes in Accounts Payable	-	1,346	862	2,394	1,165	1,405
Changes in Income Taxes Payable	-3,008	-2,845	-2,750	-2,366	-1,623	-1,743
Changes in Other Operating Activities	-510	-	-	-	-	-
Operating Cash Flow	14,221	14,575	11,861	10,345	9,808	5,963
Operating Cash Flow Growth	8.66%	22.88%	14.65%	5.47%	64.48%	24.25%
Capital Expenditures	-2,928	-2,810	-1,924	-1,361	-1,091	-1,091
Sale of Property, Plant & Equipment	20	13	55	132	282	13
Purchases of Intangible Assets	-3,546	-3,095	-2,662	-2,417	-1,480	-1,109
Proceeds from Sale of Intangible Assets	172	136	123	291	447	587
Purchases of Investments	-271	-239	-254	-216	-71	-276
Proceeds from Sale of Investments	-	-	91	32	42	785
Payments for Business Acquisitions	-1,125	-1,230	-3,779	-1,015	-820	-9,906
Other Investing Activities	331	417	370	490	-269	-61
Investing Cash Flow	-7,347	-6,808	-7,980	-4,064	-2,960	-11,058
Short-Term Debt Issued	1,599	364	-31	161	74	-552
Net Short-Term Debt Issued (Repaid)	1,599	364	-31	161	74	-552
Long-Term Debt Issued	2,005	15	6,492	3,816	-	25,858
Long-Term Debt Repaid	-2,027	-2,029	-4,652	-4,942	-1,271	-9,518
Net Long-Term Debt Issued (Repaid)	-22	-2,014	1,840	-1,126	-1,271	16,340
Issuance of Common Stock	42	40	38	33	29	29
Repurchase of Common Stock	-647	-521	-81	-	-	-
Net Common Stock Issued (Repurchased)	-605	-481	-43	33	29	29
Common Dividends Paid	-4,911	-4,971	-4,629	-4,481	-4,364	-3,856
Other Financing Activities	-630	-442	-1,133	-1,154	-1,418	-687
Financing Cash Flow	-4,570	-7,544	-3,996	-6,567	-6,823	3,649
Effect of Exchange Rate Changes on Cash and Cash Equivalents	3	46	-93	-60	-80	-62
Net Cash Flow	2,307	269	-208	-346	-55	-1,508
Free Cash Flow	11,293	11,765	9,937	8,984	8,717	4,872
Free Cash Flow Growth	-4.01%	18.40%	10.61%	3.06%	78.92%	26.94%
FCF Margin	18.68%	20.03%	18.38%	19.61%	19.65%	13.02%
Free Cash Flow Per Share	3.62	3.77	3.18	2.88	2.79	1.71
Levered Free Cash Flow	11,335	9,244	11,589	8,375	9,963	22,578
Unlevered Free Cash Flow	10,890	12,009	10,849	10,464	12,819	6,220

Updated Apr 29, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q